Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Whitlock

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Journal of Hematology & Oncology|September 8, 2016
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyDenise Niewerth, Gertjan J L Kaspers, Gerrit Jansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudyDarren R Hargrave, Eric Bouffet, Uri Tabori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortiumTanya M Trippett, Cynthia Herzog, James A Whitlock, et al.
Blood|May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes diseaseOussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
JAMA|March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialPatrick A Brown, Lingyun Ji, Xinxin Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid TumorsMark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
Haematologica|February 3, 2022
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)Sarah K Tasian, Lewis B Silverman, James A Whitlock, et al.
Cancer Medicine|February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in CanadaSandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Journal of Hematology & Oncology|September 8, 2016
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyDenise Niewerth, Gertjan J L Kaspers, Gerrit Jansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudyDarren R Hargrave, Eric Bouffet, Uri Tabori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortiumTanya M Trippett, Cynthia Herzog, James A Whitlock, et al.
Blood|May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes diseaseOussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
JAMA|March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialPatrick A Brown, Lingyun Ji, Xinxin Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid TumorsMark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
Haematologica|February 3, 2022
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)Sarah K Tasian, Lewis B Silverman, James A Whitlock, et al.
Cancer Medicine|February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in CanadaSandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.
Pageof 8